Skip to main content

Roser Solans Laque

Institutions of which they are part

Main researcher
Systemic Diseases
Vall Hebron Institut de Recerca

Roser Solans Laque

Institutions of which they are part

Main researcher
Systemic Diseases
Vall Hebron Institut de Recerca

Research lines

Genetic bases of Behçet disease.

We are currently enrolled in this multicentre study to investigate the possible influence of the genetic background in the disease pathogenesis, and to try to establish links between genetic variations and different clinical and biological patterns. The research is led by Prof. Javier Martín from the "Instituto López-Neyra" of Parasitology, CSIC (Granada). We contribute by sending samples from our cohort of patients along with the clinical data, and reviewing the results. It is supported by a SAS grant.

IP: Roser Solans Laque

Development and validation of a consensus of a systemic disease activity index for primary Sjögren’s syndrome. EULAR Sjögren’s Task Force.

We are currently enrolled in this multicentre study supported by the “EULAR Sjögren’s Task  Force”  to elaborate and agree on a systemic disease activity index for patients with primary Sjögren’s syndrome, that will be useful in the management of the disease. This study is coordinated by Dr. Raphaele Seror from the “Service de Rheumatologie Hôpital Bicêtre”, France.

IP: Roser Solans Laque

Spanish Registry of patients with primary Sjögren’s syndrome.

This is a multicentre study supported by the Systemic Autoimmune Diseases Group (GEAS) from the Spanish Internal Medicine Society (SEMI). Its main goal consist in investigate the factors involved in extraglandular development in our country. This study is coordinated by Dr. Manel Ramos  from the Clinic Hospital, Barcelona.

IP: Roser Solans Laque

Spanish Registry of patients with Behçet disease (REGEB).

This is a multicentre study supported by the Systemic Autoimmune Diseases Group from the Spanish Internal Medicine Society. The aim of the study is to describe the different clinical forms of disease presentation in our country and the response of the disease to conventional treatment.

IP: Roser Solans Laque

Projects

Autoimmunitat i malaltia trombòtica

IP: Miguel Vilardell Tarres
Collaborators: Carmen Pilar Simeón i Aznar, Ernesto Trallero Araguas, Roser Solans Laque, Segundo Bujan Rivas, Vicenç Fonollosa Pla, José Ordi Ros, Josefina Cortes Hernandez, Fernando Martínez Valle, Jesus Castro Marrero, Albert Selva O'Callaghan
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 49920
Reference: 2009 SGR 661
Duration: 01/01/2010 - 30/04/2014

Autoimmunitat i malaltia trombòtica

IP: Miguel Vilardell Tarres
Collaborators: Carmen Pilar Simeón i Aznar, Roser Solans Laque, Antonio San Jose Laporte, Vicenç Fonollosa Pla, José Ordi Ros, Albert Selva O'Callaghan, Maria Urquizu Padilla
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding:
Reference: 2005SGR 00279
Duration: 01/01/2006 - 31/12/2008

Related news

15 researchers from the Rheumatology, Systemic Diseases and the Physiology and Pathophysiology of the Digestive Tract groups gave around 25 presentations.

The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.

Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.

Related professionals

Silvia Sauleda Oliveras

Silvia Sauleda Oliveras

Transfusional Medicine
Read more
Estrella Caballero Requero

Estrella Caballero Requero

Microbiology
Read more
Francesc Casellas Jordá

Francesc Casellas Jordá

Physiology and Pathophysiology of the Digestive Tract
Read more
Carlos Jacas Escarcellé

Carlos Jacas Escarcellé

Senior researcher
Psychiatry, Mental Health and Addictions
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.